Phase 2 N=55 A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Crohn Disease
Primary: Adverse Events — 43 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=154 Intravenous Ketamine Plus Neurocognitive Training for Depression
Depression
Primary: Montgomery Asberg Depression Scale — 19.72; 22.87; 23.51 score on a scale — p=.0004
Phase 2 N=30 Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
GVHD, Chronic
Primary: Overall Response Rate (ORR) — 73.3 percentage of participants
Phase 2 N=248 A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Erosive Esophagitis
Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants
Phase 2 N=51 A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
COVID-19
Primary: Incidence of Hospitalization for COVID-19 — 0 Participants
Phase 2 N=24 Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Melanoma · Lung Cancer
Primary: Phase 2, Overall Response — 0; 0; 0; 0 Participants
Phase 2 N=49 The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application) — 6.72; -3.37 scores on a scale
Phase 2 N=3 Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Myelofibrosis
Primary: Number of Patients That Achieve Stable Disease or Clinical Improvement — 3; 4; 1; 3 Participants
Phase 2 N=22 A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Corneal Endothelial Dystrophy · Fuchs Endothelial Corneal Dystrophy · Pseudophakic Bullous Keratopathy
Primary: DLTs/ Adverse Reactions — 0; 0; 0; 0 Participants
Phase 2 N=27 Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
Alcohol-Related Disorders · Alcohol Drinking · Alcoholism
Primary: Weekly Change in Drinking — -11.4; -22.2; -39.6; -29.3 score on a scale
Phase 2 N=82 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Respiratory Syncytial Virus
Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) — 93.64; 62.53; 73.75; 78.34 days x Score
Phase 2 N=98 An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) — 74.6; 46.2 Percentage of Participants
Phase 2 N=42 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Breast Cancer
Primary: Phase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both — 100; 65; 100 percentage of participants
Phase 2 N=18 Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 50.0; 10.0 Percentage of participants
Phase 2 N=26 A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Pharmacokinetics (PK): Clearance of Mirikizumab — 0.000190 Liters per hour per kilogram (L/hr/kg)